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Introduction {#sec1}
============

Fibroblasts exert high forces that are implicated in the morphogenetic rearrangement of extracellular matrices (ECMs) ([@bib27]). In the developing mammary gland, stromal cell-mediated organization of the ECM regulates mammary ductal morphogenesis ([@bib7], [@bib30]). Despite this important function, investigations into mammary stromal components are secondary to that of the mammary epithelium. In addition to ECM organization in normal tissue, mammary gland stromal fibroblasts (MSFs) play a central role in the pro-invasive stiffening of breast tumor stroma ([@bib45]), and therefore, understanding the mechanical aspects of these cells is of clinical interest. Although the role of integrins as cell mechanosensors and transducers is well established, the link between the regulation of integrin activity and the mechanosensing response on different ECM ligands remains poorly understood. SHARPIN is a cytosolic adaptor protein that, among other functions, binds to the intracellular integrin alpha tails and inhibits integrin activity in different cell types *in vitro* and *in vivo* ([@bib33], [@bib49], [@bib50], [@bib54], [@bib56]). We have previously demonstrated that stromal SHARPIN deficiency interferes with normal mouse mammary gland development and collagen fiber assembly *in vivo* ([@bib49]). However, how SHARPIN mediates integrin-dependent mechanotransduction remains unresolved.

Collagen is abundant in the mammary gland stroma and plays a key role in regulating the physical and biochemical properties of the mammary gland. Alignment of stromal collagen bundles is critical for normal mammary gland development providing migration cues to the outgrowing duct during puberty ([@bib7], [@bib30]). There are four collagen-binding integrin heterodimers in mammals: the more ubiquitously expressed α1β1, α2β1, and α11β1 and the cartilage-specific α10β1 ([@bib69]). Of these, the fibrillar collagen-binding integrins α2β1 and α11β1 have been strongly linked to collagen remodeling and turnover ([@bib1], [@bib31], [@bib53], [@bib57], [@bib63]) and α11β1 to the induction of cancer stromal stiffness ([@bib45], [@bib68]). Furthermore, "trail blazer" breast cancer cells with high invasive capacity are characterized by high integrin α11β1 expression ([@bib66]). Nevertheless, integrin α11β1 functions are rather poorly understood, and the role of this receptor in regulating cell-collagen interactions in the mammary gland has not been previously studied.

In order to sense the properties of the surrounding ECM, cells use dynamic molecular bonds, often referred to as molecular clutches, to exert forces within the cell boundary ([@bib19]). A molecular clutch can be defined as a dynamic link between the ECM, integrin adhesion receptors, intracellular adaptor proteins, and the actomyosin cytoskeleton ([@bib17], [@bib18]). By quantification of the molecular clutch binding dynamics, and using mathematical modeling, one can predict the average force transmission of cells to the ECM as a function of substrate stiffness ([@bib17], [@bib18]).

Here, we have combined mathematical modeling with cell biology to investigate the biomechanical properties of primary mouse MSFs and to understand how the integrin inhibitor SHARPIN affects integrin-dependent force generation and mechanotransduction. We find that, somewhat counterintuitively, in spite of having higher integrin β1 activity SHARPIN-deficient MSFs were defective in spreading on soft hydrogels with a stiffness similar to the mammary gland tissue *in vivo*. They also had faster force-induced cell-ECM unbinding rates. Interestingly, both of these defects were specific to collagen and not observed on fibronectin. The molecular clutch model predicted that increased clutch unbinding rates result in the loss of stiffness-dependent traction maximum and increased actin flow rates at low rigidities. Importantly, these predictions were recapitulated experimentally in SHARPIN-deficient primary MSFs on collagen I. SHARPIN-deficient MSFs had significantly downregulated collagen-binding integrin α11β1 levels, explaining mechanistically their unexpected inability to couple to collagen. These data highlight an important divergence in the regulation of collagen I- and fibronectin-binding integrin heterodimers in the mammary gland stroma with implications for the mechanical response of fibroblasts. Moreover, these insights are likely to improve our understanding of fibrotic diseases including cancer where fibroblasts exhibit deregulated integrin activity ([@bib21], [@bib24]).

Results {#sec2}
=======

Increased Integrin Activity Correlates with Reduced Spreading of Mouse Mammary Gland Fibroblasts on Soft Collagen I, but Not on Soft Fibronectin, -Coated Matrices {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on previous observations that primary MSFs from SHARPIN-deficient mice (chronic proliferative dermatitis null mutation, *cpdm*; *Sharpin*^*cpdm/cpdm*^*; Sharpin*^*cpdm*^) ([@bib29], [@bib61]) have increased integrin β1 activity but, counterintuitively, impaired capacity to contract collagen gels ([@bib49]), we sought to investigate the link between integrin activity and force transduction. We first confirmed by flow cytometry the cell-surface levels of total and active integrin β1 with conformation-specific antibodies. As expected, *Sharpin*^*cpdm*^ MSFs expressed lower total integrin β1 cell-surface levels but equal levels of active integrin β1 compared with SHARPIN-expressing (*Sharpin*^*+*/+^or *Sharpin*^*cpdm*/+^; from here on referred to as wild-type) cells, indicating that in *Sharpin*^*cpdm*^ MSFs a higher proportion of integrin β1 is in the active conformation on the cell surface ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A), in line with our previous studies with MSFs ([@bib49]) and other cell types ([@bib50], [@bib56]). Next, we studied the ability of wild-type and *Sharpin*^*cpdm*^ MSFs to spread in response to ECM stiffness and ligand type. MSFs were seeded at equal density on soft (2 kPa) fibronectin or collagen I (a saturating concentration of 20 μg/mL of each ligand was used, [Figure S1](#mmc1){ref-type="supplementary-material"}B) pre-coated polyacrylamide gels, approximating the stiffness of the mammary tissue *in vivo* ([@bib40], [@bib49], [@bib51]). As expected based on the higher integrin β1 activity and faster focal adhesion (FA) turnover compared with wild-type MSFs ([@bib49], [@bib56]), *Sharpin*^*cpdm*^ MSFs spread more compared with wild-type MSFs when seeded on fibronectin-coated hydrogels ([Figures 1](#fig1){ref-type="fig"}B and1C). In contrast, on 2 kPa collagen-I-coated hydrogels *Sharpin*^*cpdm*^ MSFs were less spread than wild-type MSFs ([Figures 1](#fig1){ref-type="fig"}B and1C). When cell spreading area was measured on a stiffness range from 0.8 to 13 kPa ([Figure 1](#fig1){ref-type="fig"}C), on collagen-I-coated hydrogels, wild-type MSFs displayed a spreading optimum on 2 kPa, whereas *Sharpin*^*cpdm*^ MSFs were significantly smaller and only fully spread at 13 kPa ([Figure 1](#fig1){ref-type="fig"}C). These data present an unexpected conundrum; at lower stiffness \[corresponding to the higher end of the rigidity spectrum reported for mammary gland tissue *in vivo,* 0.1--2 kPa ([@bib49], [@bib51])\], loss of SHARPIN (coinciding with increased integrin β1 activity) correlates with defective MSF spreading on collagen I, whereas on fibronectin the opposite is observed.Figure 1Increased Integrin Activity Correlates with Reduced Spreading of MSFs on Soft Collagen I(A) Quantification of relative integrin β1 activity \[active (clone, 9EG7)/total (clone, HMβ1-1)\] cell-surface levels (n = 7 independent experiments) in *Sharpin*^*cpdm*^ compared with wild-type MSFs by flow cytometry.(B) Representative images of wild-type and *Sharpin*^*cpdm*^ MSFs plated for 3--4 h on 2 kPa fibronectin (upper panel) or collagen I (lower panel)-coated polyacrylamide (PAA) hydrogels and labeled for F-actin (white) and nuclei (blue). Cell edges are outlined with yellow dashed lines.(C) Quantification of cell spreading in wild-type compared with *Sharpin*^*cpdm*^ MSFs on 0.8, 2, 4, and 13 kPa PAA hydrogels coated with fibronectin (upper panel) or collagen I (lower panel) based on immunofluorescence. Data are pooled from three independent experiments, n~wt~= 90, 95, 103, 88 and n~Sharpincpdm~= 72, 80, 93, 88 cells (fibronectin, from left to right) and n~wt~= 64, 105, 91, 109 and n~Sharpincpdm~= 59, 118, 97, 77 cells (collagen I, from left to right).(D) Representative output images of FA analysis for individual cells plated on 2 kPa collagen-I-coated PAA hydrogels (FA, red; cell borders, black).(E and F) Quantification of the number of FA per cell (E) and the length of FA (F) in wild-type compared with *Sharpin*^*cpdm*^ MSFs plated on collagen-I-coated 0.8, 2, 4, and 13 kPa PAA hydrogels. Data are pooled from three independent experiments, n~wt~= 64, 94, 73, 83, n~Sharpincpdm~= 59, 97, 73, 56 cells (\# Adhesion per cell, from left to right), and n~wt~= 41, 94, 73, 109 and n~Sharpincpdm~= 42, 98, 74, 73 cells (Adhesion length, from left to right).Mean ± SEM in all graphs. Mann--Whitney *U*-test; red lines below p values indicate the data points compared. Scale bars: 20 μm. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Given that *Sharpin*^*cpdm*^ MSFs have faster FA dynamics (increased assembly and disassembly rates) on collagen-coated rigid glass substrate ([@bib49]), we next evaluated the effect of SHARPIN deficiency on FA maturation (number and average length) on a range of hydrogel rigidities. Vinculin, a mechanosensitive adaptor molecule recruited to mature FA ([@bib12], [@bib15]), was immunolabeled in wild-type and *Sharpin*^*cpdm*^ MSFs plated on 0.8--13 kPa collagen-I-coated hydrogels ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C). Wild-type and *Sharpin*^*cpdm*^ MSFs ([Figure 1](#fig1){ref-type="fig"}D) demonstrated similar FA number and length on collagen-I-coated hydrogels ([Figures 1](#fig1){ref-type="fig"}E and 1F). Interestingly, both wild-type and *Sharpin*^*cpdm*^ primary MSFs formed mature, vinculin-containing adhesions on soft matrices reaching the maturation maxima already on 2--4 kPa ([Figure 1](#fig1){ref-type="fig"}F). On fibronectin, *Sharpin*^*cpdm*^ MSFs demonstrated either longer or more FA on 2--4 kPa hydrogels ([Figures S1](#mmc1){ref-type="supplementary-material"}D--S1F), consistent with increased cell spreading ([Figures 1](#fig1){ref-type="fig"}B and1C). Furthermore, MSFs exhibited nuclear localization of the mechanosensitive transcription factor Yes-associated protein (YAP) at 2 kPa stiffness ([Figure S1](#mmc1){ref-type="supplementary-material"}G). This localization was reduced in *Sharpin*^*cpdm*^ MSFs ([Figure S1](#mmc1){ref-type="supplementary-material"}G, H). The nuclear localization of YAP and the ability of MSFs to generate elongated, stress-fiber-linked adhesions on a low stiffness are counter to the stiffness-induced adhesion reinforcement/maturation and nuclear YAP translocation detected in other cell types ([@bib18]), possibly mirroring the adaption of these primary cells to their soft growth environment in the mammary gland ([@bib40], [@bib49], [@bib51]). In conclusion, *Sharpin*^*cpdm*^ MSFs demonstrate reduced capacity to spread on soft collagen I-coated matrices, whereas the opposite occurs on fibronectin-coated substratum.

Increased Integrin Activity Correlates with Faster Integrin-Collagen Binding Dynamics in MSFs {#sec2.2}
---------------------------------------------------------------------------------------------

We then assessed how the altered integrin activity in *Sharpin*^*cpdm*^ MSFs affects the binding and unbinding properties of the cells to matrix ligands ([Figure 2](#fig2){ref-type="fig"}A). For this we employed ECM-coated bead recruitment and detachment experiments. Previous studies indicate that adhesions formed by cells on beads of comparable size \[3 μm vs. 2.8--4.5 μm; ([@bib26], [@bib32])\] have similar attachment times \[30 min vs. 20-35 min; ([@bib25], [@bib32])\] and recruit the same core-adhesome proteins as the adhesions that form on the basal side of adherent cells ([@bib26], [@bib32]). *Sharpin*^*cpdm*^ MSFs displayed slightly increased recruitment of integrin β1 to collagen-I-coated silica beads when compared with wild-type cells, whereas no significant differences in binding to fibronectin-coated beads were observed ([Figure 2](#fig2){ref-type="fig"}B). We then employed a magnetic tweezers setup ([@bib17]), a method that allows quantitative measurement of the strength of receptor-ligand bonds, to apply force to collagen I or fibronectin-coated beads attached to cells, and evaluated the time required to detach beads from cells ([Figure 2](#fig2){ref-type="fig"}A). Detachment times of collagen-coated beads were significantly lower for *Sharpin*^*cpdm*^ MSFs compared with wild-type cells ([Figure 2](#fig2){ref-type="fig"}C). However, no significant differences were observed with fibronectin-coated beads ([Figure 2](#fig2){ref-type="fig"}C). The significant decrease in bead detachment time under force suggests that unbinding rates under force are increased. Thus, overall the results are consistent with an effect of SHARPIN deficiency in increasing both binding and unbinding rates of integrins to collagen, thereby maintaining the overall recruitment constant.Figure 2SHARPIN-Deficient MSFs Show Faster Integrin-Collagen Binding Dynamics(A) Schematic representation of the set up for integrin recruitment (left panel) and magnetic tweezer (right panel) experiments.(B) Quantification of integrin β1 recruitment to collagen I (left panel) or fibronectin (right panel)-coated silica beads; n~wt~ = 62 and n~Sharpincpdm~ = 51 cells (collagen I) and n~wt~ = 33 and n~Sharpincpdm~ = 24 cells (fibronectin) from two independent experiments.(C) Quantification of detachment time of wild-type and *Sharpin*^*cpdm*^ MSFs from collagen I (left panel) or fibronectin (right panel)-coated magnetic beads; n~wt~ and n~Sharpincpdm~ = 34 cells (collagen) and n~wt~ = 29 and n~Sharpincpdm~ = 37 cells (fibronectin) from two independent experiments. Mean ± SEM in all graphs. Unpaired t test. Col I, collagen I; FN, fibronectin.

Molecular Clutch Model Predicts the Absence of Traction Peak in Sharpin^cpdm^ Cells at Biologically Relevant Rigidities {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------

The ability of cells to sense and respond to rigidity, and apply force to the matrix, is regulated by the different components of the adhesive and contractile molecular machinery that functions jointly as a cellular molecular clutch ([@bib9], [@bib10], [@bib17]). Clutch dynamics are a function of several parameters: the number and binding dynamics of integrin-ECM bonds, reinforcement of the integrin-actin link through talin unfolding and vinculin recruitment, actomyosin contractility, and substrate compliance. Unlike previously studied cell types ([@bib18]), the MSFs are able to generate fully mature adhesions at low stiffness. This suggests that MSFs should exhibit the fundamental prediction of the molecular clutch, a biphasic force/rigidity relationship, which is almost always masked by the fact that adhesion growth and reinforcement normally occur only at high rigidities ([@bib10], [@bib18]). This exciting scenario prompted us to measure the remaining necessary parameters required for computational modeling of the molecular clutch in these cells. Actomyosin contractility is an important component of the molecular clutch and is regulated by phosphorylation of myosin light chain 2 (pMLC2). In *talin 1−/−* knockout mouse embryonic fibroblasts (MEFs) (talin 1^−/−^ MEFs), which display a wild-type phenotype due to compensatory upregulation of endogenous talin 2 and have previously been studied with comparable methods ([@bib18]), pMLC2 levels are largely independent of substrate stiffness ([@bib18]). We compared our MSFs with the talin 1^−/−^ MEFs and observed increasing pMLC2 levels in MSFs in response to increasing stiffness ([Figures 3](#fig3){ref-type="fig"}A, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B), similar to the previously observed response of vascular smooth muscle cells ([@bib52]). Furthermore, higher pMLC was observed in MSFs plated on soft substrate as compared with talin 1 ^−/−^ MEFs ([@bib18]) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). However, no significant differences in pMLC2 were detected between wild-type and *Sharpin*^*cpdm*^ MSFs, suggesting that myosin activity remains predominantly unaffected in the absence of SHARPIN.Figure 3Molecular Clutch Model Predicts the Absence of Traction Peak in SHARPIN-Deficient Cells at Biologically Relevant Rigidities(A) Quantification of relative pMLC2 expression levels in wild-type compared with *Sharpin*^*cpdm*^ MSFs plated on collagen-I-coated PAA hydrogels with the indicated stiffness; n = 3 independent experiments.(B) Prediction of the traction forces generated by wild-type and *Sharpin*^*cpdm*^ MSFs on collagen-I-coated PAA hydrogels based on the molecular clutch model. The stiffness range covered in (C) is highlighted.(C) Average forces exerted by wild-type compared with *Sharpin*^*cpdm*^ MSFs on collagen-I-coated PAA hydrogels with the indicated stiffness measured by traction force microscopy, n~wt~ = 20, 20, 21, 20, 19 and n~Sharpincpdm~ = 18, 25, 21, 18, 17 cells (from left to right) from two independent experiments.(D) Average forces exerted by wild-type compared with *Sharpin*^*cpdm*^ MSFs on fibronectin-coated PAA hydrogels with the indicated stiffness measured by traction force microscopy, n~wt~= 11, 11, 23, 14, 10 and n~Sharpincpdm~= 10, 13, 23, 11, 10 cells (from left to right) from two independent experiments.(E) Representative images of Lifeact-GFP-transfected wild-type and *Sharpin*^*cpdm*^ MSFs plated on 2 kPa collagen-I-coated PAA hydrogels. Insets are kymographs showing actin retrograde flow along the red line (time = 125s, imaged every second). The slope of the line was used to calculate the actin retrograde flow rate.(F) Quantification of actin retrograde flow in wild-type compared with *Sharpin*^*cpdm*^ MSFs, n~wt~ = 10 and n~Sharpincpdm~ = 8 cells (1 measurement/cell), from three independent experiments.Mean ± SEM in all graphs. Mann--Whitney *U*-test, red lines below p values indicate the data points compared. Scale bars: 10 μm. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Taking into consideration these experimentally determined MSF features, we employed the computational model of the molecular clutch ([@bib17], [@bib18]). It predicts that in the absence of changes in integrin recruitment or adhesion growth as a function of stiffness, the cells should display a biphasic force/rigidity response, even if myosin contractility increases with rigidity ([Figure 3](#fig3){ref-type="fig"}B). The other prediction arising from our modeling is that increased integrin binding and unbinding rates, as observed in *Sharpin*^*cpdm*^ MSFs, should displace the traction force peak to higher rigidities. To test the model predictions, we measured cell-matrix force transmission using traction force microscopy. As predicted, wild-type cells on collagen I displayed a biphasic response of force as a function of stiffness, on the lower stiffness range, with a force maximum at 2 kPa ([Figure 3](#fig3){ref-type="fig"}C and[S2](#mmc1){ref-type="supplementary-material"}C). Thus, MSFs represent the first mammalian primary cell type that shows this predicted biphasic force response without genetic perturbation. In *Sharpin*^*cpdm*^ cells, the concomitant increase in binding and unbinding rates should shift the force curve, displacing the force peak to higher rigidities. Accordingly, the maximum force peak at 2 kPa was absent ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C), closely replicating the result of the molecular clutch modeling ([Figure 3](#fig3){ref-type="fig"}B). In this case, no force peak was observed, potentially because it was displaced to a stiffness above the range where traction forces were measured experimentally. Of note, wild-type cells exhibit a stiffness-dependent additional increase in force transmission above 4 kPa that is not predicted by the model indicating that the modeling corresponds to the experimental data only in the lower stiffness range. The nature of this regime remains unknown and warrants further investigation.

Finally, the molecular clutch model also predicts that changes in force should inversely correlate with actin flow. As predicted, actin flow of actively spreading (plated for 45--105 min) *Sharpin*^*cpdm*^ cells (average 51 nm/s) on 2 kPa collagen-I-coated hydrogels was also elevated with respect to wild-type cells (average 35 nm/s) ([Figures 3](#fig3){ref-type="fig"}E and3F). Because of the limited transfection efficiency in the primary MSFs and the need to isolate them freshly from mouse mammary gland, this single stiffness was selected based on the highest differences in traction force measurements. Interestingly, in stably adhered MSFs (plated for 4 h) on 2 kPa collagen-I-coated hydrogels, very slow actin retrograde flow was observed compared to talin 1^−/−^ MEFs ([Figure S2](#mmc1){ref-type="supplementary-material"}D), and measurement of actin flow in MSFs was beyond the detection limit. This is in stark contrast to the rapid actin flow detected in other cell types on soft substrate ([@bib3], [@bib10], [@bib18]), further demonstrating the adaption of MSFs to a soft environment. This may be attributed, in part, to integrin expression. We compared the cell-surface levels of several integrin subunits in talin 1^−/−^ MEFs and wild-type MSFs and observed that MSFs express nearly two times more integrin β1 and markedly more integrin α1-and α11-subunits compared to talin 1^−/−^ MEFs ([Figure S2](#mmc1){ref-type="supplementary-material"}E) that spread poorly on soft collagen ([Figure S2](#mmc1){ref-type="supplementary-material"}F).

Consistent with the fact that no differences in adhesion behavior under force were observed with fibronectin-coated beads ([Figure 2](#fig2){ref-type="fig"}C), wild-type and *Sharpin*^*cpdm*^ cells exerted the same forces on fibronectin-coated substrates irrespective of stiffness and the cells displayed monotonic increase in force with increasing rigidity ([Figure 3](#fig3){ref-type="fig"}D). In contrast to collagen I substrate, MSFs did not show a force maximum at low rigidities on fibronectin. As in *Sharpin*^*cpdm*^ cells on collagen, this lack of a biphasic force response could result from the limited stiffness range used in these experiments (0.6--14.5 kPa) and suggests that the force maximum for MSF on fibronectin is exerted at a stiffness above 14.5 kPa. Our observations support the view that different integrin heterodimers form integrin-ligand bonds with different strengths depending also on ECM composition, which leads to variations in the force maximum on different ECM ligands.

Together, these data demonstrate that SHARPIN deficiency, and the consequent increase in integrin-collagen unbinding rate, lead to significant effects in mechanotransduction in MSFs, providing a possible explanation to our previous finding that *Sharpin*^*cpdm*^ MSFs are unable to remodel collagen *in vitro* and are defective in supporting generation of mammary gland stromal architecture supportive of normal development and ductal outgrowth ([@bib49]).

Integrin α11β1 Protein Levels Regulate the Spreading of MSFs on Soft Matrices {#sec2.4}
-----------------------------------------------------------------------------

Next, we asked how loss of SHARPIN could affect integrin binding dynamics and what the consequent effects are. One potential explanation is that *Sharpin*^*cpdm*^ and wild-type MSFs exhibit differences in collagen-binding integrin expression, leading to different ECM binding properties. An RNA sequencing dataset of wild-type and *Sharpin*^*cpdm*^ MSFs ([@bib49]) was analyzed for all the matrix-binding integrin subtypes ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Of the collagen-binding integrin alpha subunits (*Itga1, Itga2, Itga10, Itga11*), which all form a heterodimer with the integrin β1 subunit, *Itga11* was the predominant α-subunit expressed at mRNA level, *Itga1* was detected at low levels and *Itga10* or *Itga2* were not detected. Importantly, no significant differences in integrin mRNA expression levels were observed between wild-type and *Sharpin*^*cpdm*^ MSFs ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

Next we analyz Pa collagen-I-coated hydrogels directly after isolation from the mouse mammary gland ([Figure S3](#mmc1){ref-type="supplementary-material"}B), indicating that the observed difference in integrin α11 is not induced by *in vitro* culture on stiff fibronectin-rich substratum (plastic in the presence of serum fibronectin) and is prominent under conditions when collagen I is the only provided ligand ([Figure S3](#mmc1){ref-type="supplementary-material"}C).

As inactive and active integrins are trafficked and degraded differently ([@bib2], [@bib55]), we speculated that the increased relative activity of integrin β1 could lead to increased targeting of integrin α11β1 to lysosomal degradation in *Sharpin*^*cpdm*^ MSFs. This hypothesis was supported by the fact that SHARPIN-deficient MSFs displayed more integrin α11 co-localization with Lamp1 (lysosomal marker) than wild-type MSFs ([Figures 4](#fig4){ref-type="fig"}G and 4H). Furthermore, we observed accumulation of integrin α11 to the Lamp1-positive compartment when MSFs were treated with the lysosomal degradation disruptor Bafilomycin A1 ([Figures 4](#fig4){ref-type="fig"}G and 4H). These data suggest that a subset of integrin α11 traffics to lysosomal degradation in MSFs and that this is enhanced in SHARPIN-deficient cells.Figure 4SHARPIN Regulates Integrin α11β1 Protein Levels(A) Analysis of cell-surface expression (median fluorescence) of integrin α1 and α11 in *Sharpin*^*cpdm*^ relative to wild-type MSFs, n~Itga1~ =6 and n~Itga11~ = 8 from six independent flow cytometry experiments.(B and C) (B) Representative Western blot analysis of integrin α11 protein expression in wild-type and *Sharpin*^*cpdm*^ MSFs and (C) quantification of the relative integrin α11 expression levels, n~wt~ and n~Sharpincpdm~ = 7 from five independent experiments. GAPDH was detected for loading control.(D) Representative images of immunolabelled integrin α11 (green) and total integrin β1 (magenta) in wild-type and *Sharpin*^*cpdm*^ MSFs plated on 2 kPa collagen-I-coated PAA hydrogels. Nuclei (blue) were co-labeled.(E and F) (E) Representative Western blot analysis of integrin α11 and SHARPIN protein expression in wild-type MSFs silenced with control or SHARPIN-targeting siRNA and (F) quantification of the relative integrin α11 expression levels; n = 5 independent experiments. GAPDH was detected for loading control.(G) Representative images of immunolabelled integrin α11 (green) and the lysosomal marker Lamp1 (magenta) in control-treated (ctrl) or Bafilomycin A1-treated (100 nM, 6h) wild-type and *Sharpin*^*cpdm*^ MSFs plated on collagen. Region of interest (yellow) shows examples of co-localization (white spots, highlighted with red arrow).(H) Quantification of relative (to wt control) co-localization of integrin α11 and Lamp1 in control-treated or Bafilomycin-A1-treated wild-type and *Sharpin*^*cpdm*^ MSFs plated on collagen; n = 76, 102, 89, 125 cells (from left to right) pooled from three independent experiments; line under p value indicates which samples are compared with each other.Mean ± SEM in all graphs. (A) Wilcoxon matched-pairs signed rank test. (C, F, and H) Mann-Whitney *U*-test. Scale bars: 20 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To investigate whether the reduced surface expression of integrin α1 and α11 in *Sharpin*^*cpdm*^ MSFs could be responsible for the impaired capability to spread on a compliant collagen-I-coated surface, we analyzed cell spreading following siRNA-mediated downregulation of integrin α1 or integrin α11 ([Figure 5](#fig5){ref-type="fig"}A), confirmed by qPCR ([Figure S3](#mmc1){ref-type="supplementary-material"}D). In wild-type MSFs downregulation of integrin α11, but not integrin α1, led to significantly reduced cell spreading on 2 kPa collagen-I-coated hydrogels that resembled the phenotype of *Sharpin*^*cpdm*^ MSFs ([Figure 1](#fig1){ref-type="fig"}B). In contrast, no significant differences in cell area were observed when the endogenously lower integrin α1 and integrin α11 levels were silenced in *Sharpin*^*cpdm*^ MSFs ([Figure 5](#fig5){ref-type="fig"}A). These data indicate that appropriate levels of integrin α11, but not integrin α1, are important for regulating the spreading of MSFs on soft collagen-I-coated substrates. This could be linked to the fact that integrin α11 mediates strong binding to and contraction of fibrillar collagen I ([@bib63]), whereas integrin α1 prefers non-fibrillar collagen IV and has lower binding affinity to fibrillar collagens (types I, II, and III) ([@bib65]). However, this remains to be investigated.Figure 5Integrin α11β1 Regulates the Spreading of MSFs on Soft Matrices(A) Quantification of the cell area in wild-type and *Sharpin*^*cpdm*^ MSFs silenced with control, integrin α1, or integrin α11 targeting siRNA and plated on 2 kPa collagen-I-coated PAA hydrogels; n = 94, 91, 93, 82, 88, 90 cells (from left to right) from three independent experiments.(B) Representative images of integrin α11-EGFP-transfected wild-type and *Sharpin*^*cpdm*^ MSFs plated on 2 kPa collagen-I-coated PAA hydrogels and co-labeled for F-actin (magenta) and nuclei (blue).(C) Quantification of cell area in non-transfected and integrin α11-EGFP-transfected wild-type and *Sharpin*^*cpdm*^ MSFs plated on 2 kPa collagen-I-coated PAA hydrogels. Data are pooled from two independent experiments; n = 37, 31, 46, 48 cells (from left to right).(D) Quantification of detachment time of wild-type, *Sharpin*^*cpdm*^, and integrin α11-EGFP-transfected *Sharpin*^*cpdm*^ MSFs from collagen-I-coated magnetic beads. Data are pooled from three independent experiments; n = 91, 101, 46 cells (from left to right).Mean ± SEM in all graphs. (A) Unpaired t test. (C and D) Mann-Whitney *U*-test. Line under p value indicates which samples are compared with each other. Scale bars: 20 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To verify that integrin α11 levels are critical for collagen I interaction of MSFs, we performed rescue experiments with ectopically expressed EGFP-tagged human integrin α11. Reintroduction of integrin α11 in *Sharpin*^*cpdm*^ MSFs on collagen-I-coated 2 kPa hydrogels reversed their defective spreading ([Figures 5](#fig5){ref-type="fig"}B and 5C). In contrast, overexpression of integrin α11-EGFP in wild-type MSFs modestly, albeit, non-significantly decreased cell spreading ([Figures 5](#fig5){ref-type="fig"}B and 5C). In addition, reintroduction of integrin α11 by ectopic expression partially rescued the ligand detachment time in *Sharpin*^*cpdm*^ MSFs ([Figure 5](#fig5){ref-type="fig"}D). Taken together, these results demonstrate that integrin α11β1 is essential in the integrin-collagen I binding dynamics and spreading of MSFs on soft collagen-I-coated substrates and that the impaired mechanotransduction of SHARPIN-deficient MSFs is coupled to reduced integrin α11β1 protein expression level.

Discussion {#sec3}
==========

Here we have investigated the mechanotransduction of mammary gland stromal fibroblasts to gain insight into the biologically essential role of these cells in sculpting the mammary gland stromal architecture *in vivo* ([@bib49]). Taking this experimentally challenging primary cell model (compared with the immortalized cell lines studied previously) has provided two interesting and unexpected observations related to tissue-specific characteristics of mechanotransduction. First, our data comparing wild-type and SHARPIN-deficient cells provide a striking example of how, even if major mechanical regulators such as myosin contractility are not affected, merely changing integrin properties under force can dramatically affect the cell\'s mechanoresponse. Second, the fact that wild-type MSFs exhibit mature, vinculin-associated FA irrespective of matrix stiffness allowed us to decouple traction force generation from adhesion maturation, leading to the fundamental clutch model prediction of a biphasic traction-stiffness relationship that is otherwise very elusive to observe ([@bib19]).

The differential regulation of collagen- and fibronectin-binding integrins and the mechanobiological implications of these differences remain poorly understood. Here, we have investigated the consequences of SHARPIN deficiency on cell mechanosensing, integrin ligand-binding dynamics, and traction force generation and conducted computational modeling of these events. Our data demonstrate that in the absence of the integrin activity regulator SHARPIN, the protein levels of the collagen-binding integrin α11β1 are downregulated. This is likely to be the main reason for the significantly increased unbinding of SHARPIN-deficient MSFs from collagen-coated beads under force. As the remaining integrin α11β1 is more likely to be in the primed active conformation, due to the increase in relative integrin β1 activity, this could account for the small increase of integrin recruitment to collagen. These faster cell-collagen binding dynamics are in line with the previously reported rapid adhesion turnover of SHARPIN-deficient MSFs ([@bib49]). Importantly, the molecular clutch model was able to predict the absence of traction peak and increased actin flow rate at low rigidities based on increased clutch binding and unbinding rates to collagen, measured by magnetic tweezers in SHARPIN-deficient cells. Of note, whereas the response to force of integrin-collagen bonds is not known, our model assumed a catch bond behavior. This should, however, not affect our conclusions, because the key aspects of the molecular clutch model found here (biphasic behavior, plus the role of fold changes in binding and unbinding rates) are general to both catch and slip bonds ([@bib4]).

Our model failed, however, to predict the final increase in force transmission in wild-type cells with increasing stiffness. Although the details of this regime warrants further investigation, we note that in conditions with very low actin flow rates, mature adhesions, and very stable actin fibers, cytoskeletal reorganization events other than fast actin flow could be determinant of the cellular force transmission ([@bib46]). In all, we acknowledge that the model prediction corresponds to the experimental data only in the soft stiffness range, possibly because not all cellular parameters have been, and can be, taken into account by the molecular clutch model.

Although SHARPIN regulates the activity of both collagen- and fibronectin-binding integrins ([@bib56]), the low levels of fibrillar collagen-binding integrin α11 in SHARPIN-deficient MSFs results in different mechanosensitive responses of these cells on collagen and fibronectin. This is in line with the established role of integrin α11β1 ([@bib37]), in the regulation of collagen contractility ([@bib53], [@bib63]) and in collagen-linked disease conditions, such as fibrosis, cancer invasion, and particularly in cancer-associated fibroblasts ([@bib5], [@bib45]). The regulatory pathways modulating the activity of collagen-binding integrins may be distinct from other integrin heterodimers. The vast majority of studies investigating integrin activation are based on the platelet-specific integrin αIIbβ3 and the fibronectin receptors integrin α5β1 and αvβ3, which are primarily regulated by inside-out and outside-in signaling. In turn, only a few studies have addressed activity regulation in the context of collagen-binding integrins. Heterodimerization of α1β1 and α2β1 integrins has been postulated to have a key role in their activity regulation based on the lower affinity of integrin α1 and α2 to integrin β1 ([@bib41]). Thus, regulation of the expression levels of collagen-binding integrins may be particularly important for their ligand-binding dynamics.

SHARPIN is a multifunctional adapter protein that has been implicated in a number of other signaling pathways, including inhibition of integrin activity ([@bib33], [@bib49], [@bib50], [@bib54], [@bib56]). SHARPIN promotes canonical Nuclear factor (NF)-κB activation ([@bib23], [@bib64]) and other inflammatory signaling cascades as part of the linear ubiquitin assembly complex (LUBAC) ([@bib11], [@bib16], [@bib60], [@bib67]). Furthermore, SHARPIN regulates the functions of the Arp2/3 protein complex ([@bib34]), T cell receptor ([@bib48]), and caspase 1 ([@bib44]) in an LUBAC-independent manner and interacts with PTEN ([@bib28]), SHANK proteins ([@bib38]), and EYA transcription factors ([@bib36]). In this study, reduced integrin α11 protein levels were directly linked to mechanobiological phenotypes in SHARPIN-deficient MSFs, whereas integrin expression at the transcriptional level remained comparable to wild-type MSFs. Because NF-κB is a transcription factor that functions predominantly through regulation of gene expression, our data imply that NF-κB might not be the primary mechanism involved in the regulation of integrin α11 in SHARPIN-deficient MSFs. Currently, we lack the detailed mechanisms accounting for the reduced integrin α11 protein levels in SHARPIN-deficient MSFs and in wild-type MSFs upon SHARPIN silencing. However, it is likely that increased lysosomal trafficking of integrin α11, in the absence of SHARPIN, is contributing to elevated integrin degradation in these cells. This would be in line with previous studies linking integrin activation to reduced receptor recycling rates and increased lysosomal degradation ([@bib14]).

Together, our findings demonstrate how altered integrin activity in SHARPIN-deficient primary MSFs correlates with deregulated cell spreading and traction force generation in response to substrate ligand composition and stiffness. The central role for integrin α11, uncovered here, in regulating mechanotransduction on collagen may also be essential to the pathological behavior of fibroblasts in cancerous or fibrotic tissues. As both SHARPIN and integrin α11β1 are significant regulators of cancer tumorigenesis and dissemination, as well as fibroblast contractility and collagen remodeling ([@bib28], [@bib45], [@bib49], [@bib62], [@bib70]), increased understanding of their functional interplay is of wide interest. Finally, our finding that the mechanical output of fibroblasts can be strongly influenced by a single parameter of the molecular clutch, the integrin binding dynamics, highlights the tuneability of mechanotransduction and its ability to trigger specific outputs in response to both internal and external parameters.

Limitations of the Study {#sec3.1}
------------------------

Our current results indicate that absence of SHARPIN results in downregulation of integrin α11 protein levels. We find that integrin α11 localizes slightly more in lysosomes in SHARPIN-deficient than wild-type cells. This suggests that altered receptor trafficking and increased degradation may contribute partially to the lower integrin α11 expression. However, additional mechanisms, such as altered mRNA translation, may also be involved. Therefore, more follow-on studies are necessary to fully unravel the mechanism of how SHARPIN regulates integrin α11 levels.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S3, and Table S1
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